A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13

The pneumococcal conjugate vaccine (PCV) strongly protects against vaccine serotypes, but the rapid expansion of non-vaccine serotype disease and the vaccine’s high expense has reduced its overall impact. We have developed Protein Glycan Coupling Technology (PGCT) as a flexible methodology for makin...

Descripción completa

Detalles Bibliográficos
Autores principales: Reglinski, Mark, Ercoli, Giuseppe, Plumptre, Charlie, Kay, Emily, Petersen, Fernanda C., Paton, James C., Wren, Brendan W., Brown, Jeremy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208403/
https://www.ncbi.nlm.nih.gov/pubmed/30393571
http://dx.doi.org/10.1038/s41541-018-0090-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208403/
https://www.ncbi.nlm.nih.gov/pubmed/30393571
http://dx.doi.org/10.1038/s41541-018-0090-4

Ejemplares similares